Medulloblastoma
Drug research and approvals for medulloblastoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 40 studies of medulloblastoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and FDA has 0 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 40
- Trials authorized in Canada: 9
- FDA orphan approvals: 0
- EU medicines: 0
- Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic NeurofeedbackNCT07830134 · Not applicable · St. Jude Children's Research Hospital · starts Jul 26, 2026
- A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central…NCT07698899 · Phase 1 · Memorial Sloan Kettering Cancer Center · starts Jul 2, 2026
- NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High…NCT07664176 · Phase 1 · Children's National Research Institute · starts Sep 1, 2026
- Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic…NCT07584499 · Phase 1 · Sun Yat-sen University · starts May 30, 2026
- RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)NCT07492316 · Phase 1 · University of Florida · starts Apr 24, 2026
- B7-H3.CD28Z.CART in CNS NeoplasmsNCT07390539 · Phase 1 · Robbie Majzner · starts Sep 1, 2026
- Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual DiseaseNCT07346157 · Phase 1 / Phase 2 · Sabine Mueller, MD, PhD · starts Aug 21, 2026
- Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry StudyNCT07242963 · Not reported · Mohammad H. Abu Arja · starts Sep 30, 2025
- CSIMEMPHIS: Long-term Follow-up of Medulloblastoma Survivors That Received Craniospinal IrradiationNCT07085325 · Not reported · St. Jude Children's Research Hospital · starts Apr 20, 2026
Approved 1
- CarmustineGlutathione reductase inhibitor
Phase 3 12
- CyclophosphamideDNA inhibitor
- CisplatinDNA inhibitor
- CarboplatinDNA inhibitor
- VincristineTubulin inhibitor
- LomustineDNA inhibitor
- ThiotepaDNA inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- IsotretinoinRetinoic acid receptor agonist
- MethotrexateDihydrofolate reductase inhibitor
- 2-mercaptoethanesulfonic acid
- Thiosulfuric acid
- Leucovorin
Phase 2 12 of 19
- TemozolomideDNA inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- VismodegibSmoothened homolog inhibitor
- SonidegibSmoothened homolog inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- CelecoxibCyclooxygenase-2 inhibitor
- CytarabineDNA inhibitor
- Etoposide phosphateDNA topoisomerase II alpha inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
Phase 1 or earlier 11
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- ImiquimodToll-like receptor 7 agonist
- VorinostatHistone deacetylase 1 inhibitor
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- LEQ506Smoothened homolog antagonist
- AdavosertibSerine/threonine-protein kinase WEE1 inhibitor
- SilmitasertibCasein kinase II alpha inhibitor
- LabradimilBradykinin B2 receptor agonist
- PrexasertibSerine/threonine-protein kinase Chk1 inhibitor
- IndoximodmTORC1 activator
- Omburtamab
How its trials ended
210 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 44 whose ending is known, 27% met their primary endpoint, 9% missed it and 64% stopped early.
- Completed, result not reported8139%
- Ongoing7033%
- Stopped: other or unclear157%
- Status unknown157%
- Met its primary endpoint126%
- Stopped: enrollment or feasibility52%
- Missed its primary endpoint42%
- Stopped: sponsor or business decision42%
- Stopped: lack of efficacy31%
- Stopped: funding1<1%
| Jul 7, 2025 | A phase 3 study of sodium thiosulfate for reduction of cisplatin-induced ototoxicity in children with average-risk medulloblastoma and reduced therapy in…Sodium thiosulfate | Childrens Oncology Group | Ongoing |
| Jan 23, 2025 | Phase II trial of eflornithine/dfmo as maintenance therapy for molecular high risk/very high risk and relapsed/refractory medulloblastomaEflornithine (DFMO) | Beat Childhood Cancer | Ongoing |
| Oct 4, 2022 | A phase I study of savolitinib in recurrent, progressive, or refractory medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma, and CNS tumors…Savolitinib | Pediatric Brain Tumour Consortium | Closed |
| Feb 15, 2022 | Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric patients with a brain…Metformin | Hospital for Sick Children | Ongoing |
| Oct 31, 2017 | A phase 2 study of reduced therapy for newly diagnosed average-risk wnt-driven medulloblastoma patientsCyclophosphamide / Cisplatin / Vincristine | Childrens Oncology Group | Ongoing |
| May 2, 2017 | Newly diagnosed children (less than 10 years old) with medulloblastoma and other central nervous system embryonal tumors: clinical and molecular risk-tailored…Carboplatin / Cisplatin / Cyclophosphamide/ Etoposide / Etoposide phosphate /… | Next Consortium | Ongoing |
| May 22, 2015 | A clinical and molecular risk-directed therapy for newly diagnosed medulloblastomaVismodegib/ Amifostine/ Cisplatin/ Cyclophosphamide/ Pemetrexed/ Gemcitabine/… | St Jude Childrens Research Hospital | Ongoing |
| Jan 31, 2014 | A phase II study for the treatment of non-metastatic nodular desmoplastic medulloblastoma in children less than 4 years of ageVincristine/ Cyclophosphamide/ Methotrexate/ Leucovorin/ Etoposide/ Etoposide… | Childrens Oncology Group | Closed |
| Dec 20, 2013 | Placebo controlled double blind crossover trial of metformin for brain repair in children treated with cranial-spinal radiation for medulloblastomaMetformin | Hospital for Sick Children | Closed |
| Dec 15, 2021 | SilmitasertibTreatment of Medulloblastoma | Senhwa Biosciences, Inc. | Designated |
| May 9, 2019 | Genetically engineered herpes simplex virusTreatment of medulloblastoma | Aettis, Inc. | Designated |
| Jan 17, 2017 | 2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S…Diagnostic agent for the Clinical Management of Medulloblastoma | Advanced Imaging Projects, LLC | Designated |
| Mar 10, 2016 | 1,2:5,6-dianhydrogalactitolTreatment of medulloblastoma. | DelMar Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA